This invention relates to methods of crimping or mounting a stent on a balloon of a catheter assembly.
A stent, as illustrated in
Generally, stent crimping is the act of affixing the stent to the delivery catheter or delivery balloon so that it remains affixed to the catheter or balloon until the physician desires to deliver the stent at the treatment site. Current stent crimping technology is sophisticated. Examples of such technology which are known by one of ordinary skill the art include a roll crimper; a collet crimper; and an iris or sliding-wedge crimper. To use a roll crimper, first the stent is slid loosely onto the balloon portion of the catheter. This assembly is placed between the plates of the roll crimper. With an automated roll crimper, the plates come together and apply a specified amount of force. They then move back and forth a set distance in a direction that is perpendicular to the catheter. The catheter rolls back and forth this motion, and the diameter of the stent is reduced. The process can be broken down into more than one step, each with its own level of force, translational distance, and number of cycles. This process imparts a great deal of shear to the stent in a direction perpendicular to the catheter or catheter wall. Furthermore, as the stent is crimped, there is additional relative motion between the stent surface and the crimping plates.
The collet crimper is equally conceptually simple. A standard drill-chuck collet is equipped with several pie-piece-shaped jaws. These jaws move in a radial direction as an outer ring is turned. To use this crimper, a stent is loosely placed onto the balloon portion of a catheter and inserted in the center space between the jaws. Turning the outer ring causes the jaws to move inward. An issue with this device is determining or designing the crimping endpoint. One scheme is to engineer the jaws so that when they completely close, they touch and a center hole of a known diameter remains. Using this approach, turning the collet onto the collet stops crimps the stent to the known outer diameter. While this seems ideal, it can lead to problems. Stent struts have a tolerance on their thickness. Additionally, the process of folding non-compliant balloons is not exactly reproducible. Consequently, the collet crimper exerts a different amount of force on each stent in order to achieve the same final dimension. Unless this force, and the final crimped diameter, is carefully chosen, the variability of the stent and balloon dimensions can yield stent or balloon damage.
In the sliding wedge or iris crimper, adjacent sections move inward and twist, much like the leaves in a camera aperture. This crimper can be engineered to have two different types of endpoints. It can stop at a final diameter, or it can apply a fixed force and allow the final diameter to float from the discussion on the collet crimper, there are advantages in applying a fixed level of force as variability in strut and balloon dimension will not change the crimping force. The sliding wedges impart primarily normal forces. As the wedges slide over each other, they impart some tangential force. Lastly, the sliding wedge crimper presents a nearly cylindrical inner surface to the stent, even as it crimps. This means the crimping loads are distributed over the entire outer surface of the stent.
All current stent crimping methods were developed for all-metal stents. Stent metals, such as stainless steel, are durable and can take abuse. When crimping is too severe, it usually damages the underlying balloon, not the metal stent. But polymeric stents present different challenges. A polymer stent requires relatively wider struts than metal stents so as to provide suitable mechanical properties, such as radial strength. At the crimping stage, less space is provided between the struts which can result in worse stent retention than a metallic stent. Moreover, the use of high processing temperature during the crimping process to enhance stent retention may not be possible as a polymeric stent may have a glass transition temperature generally equivalent to the glass transition temperature of the balloon. Higher processing temperatures may cause the stent to lose some of its preferred mechanical properties.
The present invention provides a novel method of crimping a stent, more specifically a polymeric stent on an expandable member or a balloon.
In accordance with one embodiment, a method of crimping a stent on a balloon of a catheter assembly is provided, comprising: providing a polymeric stent disposed over a balloon in an inflated configuration; and crimping the stent over the inflated balloon to a reduced crimped configuration so that the stent is secured onto the balloon. In some embodiments, the act of providing comprises inserting a balloon in a collapsed configuration into a stent; and expanding the balloon to the inflated configuration, wherein the inflated configuration is equal to or less than the intended expansion configuration of the balloon. In some embodiments, the inflated configuration is a configuration which provides for a membrane or wall of the balloon to protrude into gaps between structural elements of the stent. As a result, subsequent to crimping the stent on the balloon, a membrane or wall of the balloon is pinched or wedged between the structural elements of the stent. During the crimping process, the pressure in the balloon can be controllably released by a valve. In some embodiments, the stent is not a metallic stent. In some embodiments, the stent is a biodegradable polymeric stent. In some embodiments, the stent is a biodegradable polymeric stent with or without a biodegradable metallic component.
In accordance with another embodiment, a method of crimping a stent on a balloon, is provided comprising the following acts in the order as listed: (a) providing a stent disposed over a balloon in an inflated configuration; (b) crimping the stent to a first reduced diameter; (c) at least partially deflating the balloon; (d) inflating the balloon to at least an inner diameter of the stent; and (e) crimping the stent to a second reduced diameter. The second reduced diameter can be the final crimped diameter.
The figures have not been drawn to scale and portions thereof have been under or over emphasized for illustrative purposes.
The stent crimping methods are suitable to adequately and uniformly crimp a balloon expandable stent onto a balloon or expandable member of a catheter assembly. The embodiments of the invention are also applicable to self-expandable stents and stent-grafts. In one embodiment, the method of the present invention is particularly directed to crimping of a biodegradable, polymeric stent on a balloon of a catheter assembly. A biodegradable polymer stent has many advantages over metal stents, including the ability to be placed in the body only for the duration of time until the intended function of the stent has been performed. However, retention of a polymer stent has been proven to be more challenging than that of a metallic stent. Polymer stents can require wider struts than metal stents so as to provide suitable mechanical properties, such as radial strength, for the stent. At the crimping stage, less space is provided between the struts which can result in worse stent retention than a metallic stent. Moreover, the use of high processing temperature during the crimping process to enhance stent retention may not be possible as a polymeric stent may have a glass transition temperature generally equivalent to, or lower than the glass transition temperature of the balloon. Higher processing temperatures may cause the polymeric stent to lose some of its preferred mechanical properties.
The balloon is illustrated in
As illustrated in
The balloon 10 can be inflated by application of a fluid or a gas. The temperature of the fluid or gas can be adjusted to other than ambient or room temperature. In one embodiment, a heated fluid or gas is used. In some embodiments, heated can be defined as above 25 deg. C. In some embodiments, the temperature can be below 200 deg. C., or alternatively below 150 deg. C., or alternatively below 100 deg. C., or alternatively below 75 deg. C. In some embodiments, the temperature can be between 25 deg. C. and 100 deg. C. In some embodiments, the temperature is equal to or above the glass transition temperature (Tg) of a polymer of the stent body or a polymer of the stent coating (if applicable). In some embodiments, the temperature is equal to or above Tg but less than melting temperature of the melting temperature of the of a polymer of the stent body or a polymer of the coating. In some embodiments, a cooled or chilled fluid or gas can be used to inflate the balloon. Cooled can mean below 25 deg. C. Chilled can mean below 0 deg. C.
In some embodiments, the crimped inflation state can include hyper-inflation of the balloon. Over or hyper-inflation is defined as any diameter or size above the intended expanded configuration but less than a diameter or size which the balloon will be damaged or no longer suitable or its intended use. Balloon diameter tolerances depend on the type of balloon and the material from which the balloon is made, among other factors. The manufacturer of the balloon can provide such information to a user, for example.
As illustrated in
Next, as illustrated in
The crimping device 20 can be any device used in the art. The stent 14 positioned over the balloon 10 is crimped to a reduced balloon and stent configuration (reduced crimped configuration), as illustrated in
Crimping can be defined as the process of mounting, fastening or securing a stent on a balloon. The stent can be fixedly carried by the balloon but can be deployed by inflation and subsequent withdrawal of the balloon in order to be implanted at a target site, such as a region of stenosis. The crimp process can include selectively, radially compressing or applying pressure for positioning a stent on a balloon of a catheter assembly or an expandable delivery member of a catheter assembly. The compression or radial pressure during crimping can be segmented or uniform across the length and/or circumference of the stent. The application of pressure by the crimping device 20 can be continuous or applied in an intermittent or stepwise fashion. In an intermittent embodiment, the balloon can be deflated and re-inflated until final crimp configuration has been achieved. In some embodiments, the crimping device can hold the pressure at the reduced crimped configuration for duration of time prior to release of pressure. The process of crimping can also include, unless otherwise specifically indicated, modification made to the stent and/or balloon prior, during or subsequent to the application of crimping pressure that are directed to retention of the stent on the balloon. For example, the balloon can be coated before crimping to improve the retention of the stent on the balloon. In some embodiments, the balloon can be dipped into a fluid or solvent such as acetone before sliding the stent on the balloon in order to soften the balloon material. This makes it easy for the balloon material to squeeze into the space between the struts or structural elements. The solvents, such as acetone, may also partially dissolve the surface of the stent or coating on the stent allowing for better adhesion between the stem and the balloon. In some embodiments, a softening fluid can be used that is a non-solvent for the stent or the coating on the sent. By way of another example, a grip process can be conducted after crimping to further increase stent retention. An outer sleeve restrains the crimped stent. Simultaneously, pressure and heat are applied to the stent section. Under this action, the balloon material deforms slightly, moving in between the struts.
Reduced balloon configuration (i.e., reduced crimp configuration) is a size or diameter greater than the size or diameter of the balloon 10 in its collapsed configuration. In some embodiments, the measured reduced size or diameter can be equivalent or generally equivalent to that of the collapsed configuration. Since the balloon 10 is pressurized by a fluid or gas, a pressure release valve 24 is provided to allow release of pressure from the balloon 10 during the crimping process. During the crimping process, the pressure release valve 24 will open to release pressure when the compression pressure caused by the crimping is higher than a set value of the valve 24. The release of the pressure is controlled so as to allow the crimper 20 to apply adequate pressure on the stent 14 for fastening the stent 14 on the balloon 10. If too much pressure is released from the balloon 10 during crimping, the stent 14 may not be adequately crimped on the balloon 10. The set pressure value of the valve depends on a variety of factors including the type of crimping device, stent, and balloon used. The calculation of the amount of applied pressure and preset valve pressure intake can be readily determined by one having skilled in the art.
As illustrated in
In some embodiments, the stent 14 is arranged on the balloon 10 so that an outside surface of the balloon 10 and an inside surface of the stent 14 contact each other to form a combination of the balloon and stent. In some embodiments, the outer surface of the balloon or the inner surface of a stent can include a coating such as an adhesive coating, a drug delivery coating, a protective coating, a polymeric coating, a blocking agent or the like. The blocking agent is intended to reduce adhesion and/or friction between the stent 14 or a coating on the stent 14 and the balloon 10.
The stent body itself is preferably made from a polymeric material such as one or a combination of polymers. In some embodiments, such body can be made from a combination of polymeric and metallic material(s). In some embodiments, the stent is biodegradable. Both polymers and metallic materials can be biodegradable. In one preferred embodiment, the stent is completely or exclusively made from a polymeric material or combination of polymeric materials, more specifically biodegradable polymer(s). A polymeric stent can include some metallic components for allowing the stent to be viewed during the procedure; however, the amount of material is insignificant, does not impart any structural function to the stent, or for viewing means only such that the stent is in essence made from a polymeric material or combination of polymers as is understood by one having ordinary skill in the art. In some embodiments, metallic stents are completely excluded from any of the embodiments of this invention. Metallic stents have a stent body (i.e., struts or structural elements) made mostly or completely from a metallic material such as an alloy. It should be noted that biodegradable is intended to include bioabsorbable, bioerodable, etc. unless otherwise specifically indicated.
In some embodiments, the stent can include a drug coating. The coating can be a pure drug or combination of drugs. The coating can include a polymeric carrier of a single or multiple polymers. The coating can be layered as is understood by one of ordinary skilled in the art.
The stent or the coating can be made from a material including, but are not limited to, poly(N-acetylglucosamine) (Chitin), Chitosan, poly(hydroxyvalerate), poly(lactide-co-glycolide), poly(hydroxybutyrate), poly(hydroxybutyrate-co-valerate), polyorthoester, polyanhydride, poly(glycolic acid), poly(glycolide), poly(L-lactic acid), poly(L-lactide), poly(D,L-lactic acid), poly(D,L-lactide), poly(caprolactone), poly(trimethylene carbonate), polyester amide, poly(glycolic acid-co-trimethylene carbonate), co-poly(ether-esters) (e.g. PEO/PLA), polyphosphazenes, biomolecules (such as fibrin, fibrinogen, cellulose, starch, collagen and hyaluronic acid), polyurethanes, silicones, polyesters, polyolefins, polyisobutylene and ethylene-alphaolefin copolymers, acrylic polymers and copolymers other than polyacrylates, vinyl halide polymers and copolymers (such as polyvinyl chloride), polyvinyl ethers (such as polyvinyl methyl ether), polyvinylidene halides (such as polyvinylidene chloride), polyacrylonitrile, polyvinyl ketones, polyvinyl aromatics (such as polystyrene), polyvinyl esters (such as polyvinyl acetate), acrylonitrile-styrene copolymers, ABS resins, polyamides (such as Nylon 66 and polycaprolactam), polycarbonates, polyoxymethylenes, polyimides, polyethers, polyurethanes, rayon, rayon-triacetate, cellulose, cellulose acetate, cellulose butyrate, cellulose acetate butyrate, cellophane, cellulose nitrate, cellulose propionate, cellulose ethers, and carboxymethyl cellulose. Another type of polymer based on poly(lactic acid) that can be used includes graft copolymers, and block copolymers, such as AB block-copolymers (“diblock-copolymers”) or ABA block-copolymers (“triblock-copolymers”), or mixtures thereof.
Additional representative examples of polymers that may be especially well suited for use in fabricating or coating the stent include ethylene vinyl alcohol copolymer (commonly known by the generic name EVOH or by the trade name EVAL), poly(butyl methacrylate), poly(vinylidene fluoride-co-hexafluororpropene) (e.g., SOLEF 21508, available from Solvay Solexis PVDF, Thorofare, N.J.), polyvinylidene fluoride (otherwise known KYNAR, available from ATOFINA Chemicals, Philadelphia, Pa.), ethylene-vinyl acetate copolymers, and polyethylene glycol.
A first polymer stent was crimped by in-house process. A second polymer stent was placed on a balloon and then inserted into the crimper. The crimper head was reduced to the stent's outer diameter. Then the balloon was inflated to stent's outer diameter or the crimper's inner diameter at the pressure of 30 psi. The stent was crimped down further under pressure or release pressure at a slow rate and then held at target crimping diameter for certain time without balloon pressure present.
Both groups were measured by Instron Tester. Bottom grip on the Instron held the balloons below the stent and the upper grip held a stent section on the balloons. The device was used to pull the stents away from the balloons by moving the upper grip in an upwards direction. The force was measured when the stents moved at least of 1 mm from the original location.
A stent can be mounted on a balloon, followed by inflating the balloon to an inner diameter of the stent. Crimp to intermediate diameter, between original diameter of the stent and final, desired diameter of the stent. The balloon can then be deflated by pulling vacuum on balloon, for example. Next, the balloon can be inflated to an intermediate diameter (diameter is controlled by position of crimping head). Crimp to final, desired diameter. This method can provide support to the stent during the initial crimping process and reduces crimping defects during the manufacturing process.
While particular embodiments of the present invention have been described, it will be obvious to those skilled in the art that changes and modifications can be made without departing from the spirit and scope of the teachings and embodiments of this invention. Therefore, the appended claims are to encompass within their scope all such changes and modifications as fall within the true spirit of this invention.
This application is a continuation of U.S. patent application Ser. No. 14/552,066, filed Nov. 24, 2014, which is a continuation of U.S. patent application Ser. No. 13/779,636, filed on Feb. 27, 2013, and now issued as U.S. Pat. No. 9,259,341 on Feb. 16, 2016; which is a continuation of U.S. patent application Ser. No. 13/551,538, filed on Jul. 17, 2012, and now issued as U.S. Pat. No. 8,925,177 on Jan. 6, 2015; which is a continuation application of U.S. patent application Ser. No. 11/471,375, filed on Jun. 19, 2006, and now issued as U.S. Pat. No. 8,333,000 on Dec. 18, 2012.
Number | Name | Date | Kind |
---|---|---|---|
3687135 | Stroganov et al. | Aug 1972 | A |
3839743 | Schwarcz | Oct 1974 | A |
3900632 | Robinson | Aug 1975 | A |
4104410 | Malecki | Aug 1978 | A |
4110497 | Hoel | Aug 1978 | A |
4321711 | Mano | Mar 1982 | A |
4346028 | Griffith | Aug 1982 | A |
4596574 | Urist | Jun 1986 | A |
4599085 | Riess et al. | Jul 1986 | A |
4612009 | Drobnik et al. | Sep 1986 | A |
4633873 | Dumican et al. | Jan 1987 | A |
4656083 | Hoffman et al. | Apr 1987 | A |
4718907 | Karwoski et al. | Jan 1988 | A |
4722335 | Vilasi | Feb 1988 | A |
4723549 | Wholey et al. | Feb 1988 | A |
4732152 | Wallsten et al. | Mar 1988 | A |
4733665 | Palmaz | Mar 1988 | A |
4739762 | Palmaz | Apr 1988 | A |
4740207 | Kreamer | Apr 1988 | A |
4743252 | Martin, Jr. et al. | May 1988 | A |
4768507 | Fischell et al. | Sep 1988 | A |
4776337 | Palmaz | Oct 1988 | A |
4800882 | Gianturco | Jan 1989 | A |
4816339 | Tu et al. | Mar 1989 | A |
4818559 | Hama et al. | Apr 1989 | A |
4850999 | Planck | Jul 1989 | A |
4877030 | Beck et al. | Oct 1989 | A |
4878906 | Lindemann et al. | Nov 1989 | A |
4879135 | Greco et al. | Nov 1989 | A |
4886062 | Wiktor | Dec 1989 | A |
4902289 | Yannas | Feb 1990 | A |
4977901 | Ofstead | Dec 1990 | A |
4990151 | Wallsten | Feb 1991 | A |
4994298 | Yasuda | Feb 1991 | A |
5019090 | Pinchuk | May 1991 | A |
5028597 | Kodama et al. | Jul 1991 | A |
5059211 | Stack et al. | Oct 1991 | A |
5062829 | Pryor et al. | Nov 1991 | A |
5084065 | Weldon et al. | Jan 1992 | A |
5085629 | Goldberg et al. | Feb 1992 | A |
5087244 | Wolinsky et al. | Feb 1992 | A |
5100429 | Sinofsky et al. | Mar 1992 | A |
5104410 | Chowdhary | Apr 1992 | A |
5108417 | Sawyer | Apr 1992 | A |
5108755 | Daniels et al. | Apr 1992 | A |
5112457 | Marchant | May 1992 | A |
5123917 | Lee | Jun 1992 | A |
5147385 | Beck et al. | Sep 1992 | A |
5156623 | Hakamatsuka et al. | Oct 1992 | A |
5163951 | Pinchuk et al. | Nov 1992 | A |
5163952 | Froix | Nov 1992 | A |
5163958 | Pinchuk | Nov 1992 | A |
5167614 | Tessmann et al. | Dec 1992 | A |
5192311 | King et al. | Mar 1993 | A |
5197977 | Hoffman, Jr. et al. | Mar 1993 | A |
5234456 | Silvestrini | Aug 1993 | A |
5234457 | Andersen | Aug 1993 | A |
5236447 | Kubo et al. | Aug 1993 | A |
5279594 | Jackson | Jan 1994 | A |
5282860 | Matsuno et al. | Feb 1994 | A |
5289831 | Bosley | Mar 1994 | A |
5290271 | Jernberg | Mar 1994 | A |
5292321 | Lee | Mar 1994 | A |
5306286 | Stack et al. | Apr 1994 | A |
5306294 | Winston et al. | Apr 1994 | A |
5328471 | Slepian | Jul 1994 | A |
5330500 | Song | Jul 1994 | A |
5342348 | Kaplan | Aug 1994 | A |
5342395 | Jarrett et al. | Aug 1994 | A |
5342621 | Eury | Aug 1994 | A |
5356433 | Rowland et al. | Oct 1994 | A |
5383925 | Schmitt | Jan 1995 | A |
5385580 | Schmitt | Jan 1995 | A |
5389106 | Tower | Feb 1995 | A |
5399666 | Ford | Mar 1995 | A |
5423885 | Williams | Jun 1995 | A |
5441515 | Khosravi et al. | Aug 1995 | A |
5443458 | Eury et al. | Aug 1995 | A |
5443500 | Sigwart | Aug 1995 | A |
5455040 | Marchant | Oct 1995 | A |
5464650 | Berg et al. | Nov 1995 | A |
5502158 | Sinclair et al. | Mar 1996 | A |
5507768 | Lau et al. | Apr 1996 | A |
5514154 | Lau et al. | May 1996 | A |
5514379 | Weissieder et al. | May 1996 | A |
5527337 | Stack et al. | Jun 1996 | A |
5545208 | Wolff et al. | Aug 1996 | A |
5545408 | Trigg et al. | Aug 1996 | A |
5549635 | Solar | Aug 1996 | A |
5554120 | Chen et al. | Sep 1996 | A |
5556413 | Lam | Sep 1996 | A |
5569295 | Lam | Oct 1996 | A |
5578046 | Liu et al. | Nov 1996 | A |
5578073 | Haimovich et al. | Nov 1996 | A |
5591199 | Porter et al. | Jan 1997 | A |
5591607 | Gryaznov et al. | Jan 1997 | A |
5593403 | Buscemi | Jan 1997 | A |
5593434 | Williams | Jan 1997 | A |
5599301 | Jacobs et al. | Feb 1997 | A |
5599922 | Gryaznov et al. | Feb 1997 | A |
5605696 | Eury et al. | Feb 1997 | A |
5607442 | Fischell et al. | Mar 1997 | A |
5607467 | Froix | Mar 1997 | A |
5618299 | Khosravi et al. | Apr 1997 | A |
5628784 | Strecker | May 1997 | A |
5629077 | Turnlund et al. | May 1997 | A |
5631135 | Gryaznov et al. | May 1997 | A |
5632771 | Boatman et al. | May 1997 | A |
5632840 | Campbell | May 1997 | A |
5637113 | Tartaglia et al. | Jun 1997 | A |
5649977 | Campbell | Jul 1997 | A |
5667767 | Greff et al. | Sep 1997 | A |
5667796 | Otten | Sep 1997 | A |
5670558 | Onishi et al. | Sep 1997 | A |
5690644 | Yurek et al. | Nov 1997 | A |
5693085 | Buirge et al. | Dec 1997 | A |
5700286 | Tartaglia et al. | Dec 1997 | A |
5707385 | Williams | Jan 1998 | A |
5711763 | Nonami et al. | Jan 1998 | A |
5716393 | Lindenberg et al. | Feb 1998 | A |
5716981 | Hunter et al. | Feb 1998 | A |
5725549 | Lam | Mar 1998 | A |
5726297 | Gryaznov et al. | Mar 1998 | A |
5728068 | Leone et al. | Mar 1998 | A |
5728751 | Patnaik | Mar 1998 | A |
5733326 | Tomonto et al. | Mar 1998 | A |
5733330 | Cox | Mar 1998 | A |
5733564 | Lehtinen | Mar 1998 | A |
5733925 | Kunz et al. | Mar 1998 | A |
5741881 | Patnaik | Apr 1998 | A |
5756457 | Wang et al. | May 1998 | A |
5756476 | Epstein et al. | May 1998 | A |
5759474 | Rupp et al. | Jun 1998 | A |
5765682 | Bley et al. | Jun 1998 | A |
5766204 | Porter et al. | Jun 1998 | A |
5766239 | Cox | Jun 1998 | A |
5766710 | Turnlund et al. | Jun 1998 | A |
5769883 | Buscemi et al. | Jun 1998 | A |
5776140 | Cottone | Jul 1998 | A |
5780807 | Saunders | Jul 1998 | A |
5782839 | Hart et al. | Jul 1998 | A |
5792144 | Fischell et al. | Aug 1998 | A |
5800516 | Fine et al. | Sep 1998 | A |
5811447 | Kunz et al. | Sep 1998 | A |
5824049 | Ragheb et al. | Oct 1998 | A |
5830178 | Jones et al. | Nov 1998 | A |
5830461 | Billiar | Nov 1998 | A |
5830879 | Isner | Nov 1998 | A |
5833651 | Donovan et al. | Nov 1998 | A |
5834582 | Sinclair et al. | Nov 1998 | A |
5836962 | Gianotti | Nov 1998 | A |
5836965 | Jendersee et al. | Nov 1998 | A |
5837313 | Ding et al. | Nov 1998 | A |
5837835 | Gryaznov et al. | Nov 1998 | A |
5840083 | Braach-Maksvytis | Nov 1998 | A |
5851508 | Greff et al. | Dec 1998 | A |
5853408 | Muni | Dec 1998 | A |
5854207 | Lee et al. | Dec 1998 | A |
5855612 | Ohthuki et al. | Jan 1999 | A |
5855618 | Patnaik et al. | Jan 1999 | A |
5858746 | Hubbell et al. | Jan 1999 | A |
5860966 | Tower | Jan 1999 | A |
5865814 | Tuch | Feb 1999 | A |
5868781 | Killion | Feb 1999 | A |
5871468 | Kramer et al. | Feb 1999 | A |
5873904 | Ragheb et al. | Feb 1999 | A |
5874101 | Zhong et al. | Feb 1999 | A |
5874109 | Ducheyne et al. | Feb 1999 | A |
5874165 | Drumheller | Feb 1999 | A |
5876743 | Ibsen et al. | Mar 1999 | A |
5877263 | Patnaik et al. | Mar 1999 | A |
5879713 | Roth et al. | Mar 1999 | A |
5888533 | Dunn | Mar 1999 | A |
5891192 | Murayama et al. | Apr 1999 | A |
5893852 | Morales | Apr 1999 | A |
5897955 | Drumheller | Apr 1999 | A |
5906759 | Richter | May 1999 | A |
5913871 | Werneth et al. | Jun 1999 | A |
5914182 | Drumheller | Jun 1999 | A |
5916870 | Lee et al. | Jun 1999 | A |
5920975 | Morales | Jul 1999 | A |
5922005 | Richter et al. | Jul 1999 | A |
5942209 | Leavitt et al. | Aug 1999 | A |
5948428 | Lee et al. | Sep 1999 | A |
5954744 | Phan et al. | Sep 1999 | A |
5957975 | Lafont et al. | Sep 1999 | A |
5965720 | Gryaznov et al. | Oct 1999 | A |
5971954 | Conway et al. | Oct 1999 | A |
5976181 | Whelan et al. | Nov 1999 | A |
5976182 | Cox | Nov 1999 | A |
5980530 | Willard et al. | Nov 1999 | A |
5980564 | Stinson | Nov 1999 | A |
5980928 | Terry | Nov 1999 | A |
5980972 | Ding | Nov 1999 | A |
5981568 | Kunz et al. | Nov 1999 | A |
5986169 | Gjunter | Nov 1999 | A |
5997468 | Wolff et al. | Dec 1999 | A |
6010445 | Armini et al. | Jan 2000 | A |
6015541 | Greff et al. | Jan 2000 | A |
6022359 | Frantzen | Feb 2000 | A |
6042875 | Ding et al. | Mar 2000 | A |
6048964 | Lee et al. | Apr 2000 | A |
6051648 | Rhee et al. | Apr 2000 | A |
6056993 | Leidner et al. | May 2000 | A |
6060451 | DiMaio et al. | May 2000 | A |
6063092 | Shin | May 2000 | A |
6066156 | Yan | May 2000 | A |
6071266 | Kelley | Jun 2000 | A |
6074381 | Dinh et al. | Jun 2000 | A |
6074659 | Kunz et al. | Jun 2000 | A |
6080177 | Igaki et al. | Jun 2000 | A |
6080488 | Hostettler et al. | Jun 2000 | A |
6082990 | Jackson et al. | Jul 2000 | A |
6083258 | Yadav | Jul 2000 | A |
6093463 | Thakrar | Jul 2000 | A |
6096070 | Ragheb et al. | Aug 2000 | A |
6096525 | Patnaik | Aug 2000 | A |
6099562 | Ding et al. | Aug 2000 | A |
6103230 | Billiar et al. | Aug 2000 | A |
6106530 | Harada | Aug 2000 | A |
6107416 | Patnaik et al. | Aug 2000 | A |
6110180 | Foreman et al. | Aug 2000 | A |
6110188 | Narciso, Jr. | Aug 2000 | A |
6113629 | Ken | Sep 2000 | A |
6117979 | Hendriks et al. | Sep 2000 | A |
6120522 | Vrba et al. | Sep 2000 | A |
6120536 | Ding et al. | Sep 2000 | A |
6120904 | Hostettler et al. | Sep 2000 | A |
6121027 | Clapper et al. | Sep 2000 | A |
6125523 | Brown et al. | Oct 2000 | A |
6127173 | Eckstein et al. | Oct 2000 | A |
6129761 | Hubbell | Oct 2000 | A |
6129928 | Sarangapani et al. | Oct 2000 | A |
6141855 | Morales | Nov 2000 | A |
6150630 | Perry et al. | Nov 2000 | A |
6153252 | Hossainy et al. | Nov 2000 | A |
6159227 | Di Caprio et al. | Dec 2000 | A |
6159951 | Karpeisky et al. | Dec 2000 | A |
6160084 | Langer et al. | Dec 2000 | A |
6165212 | Dereume et al. | Dec 2000 | A |
6166130 | Rhee et al. | Dec 2000 | A |
6169170 | Gryaznov et al. | Jan 2001 | B1 |
6171609 | Kunz | Jan 2001 | B1 |
6174330 | Stinson | Jan 2001 | B1 |
6177523 | Reich et al. | Jan 2001 | B1 |
6183505 | Mohn, Jr. et al. | Feb 2001 | B1 |
6187013 | Stoltze et al. | Feb 2001 | B1 |
6187045 | Fehring et al. | Feb 2001 | B1 |
6210715 | Starling et al. | Apr 2001 | B1 |
6224626 | Steinke | May 2001 | B1 |
6228845 | Donovan et al. | May 2001 | B1 |
6240616 | Yan | Jun 2001 | B1 |
6245076 | Yan | Jun 2001 | B1 |
6245103 | Stinson | Jun 2001 | B1 |
6248344 | Yianen et al. | Jun 2001 | B1 |
6251135 | Stinson et al. | Jun 2001 | B1 |
6251142 | Bernacca et al. | Jun 2001 | B1 |
6264683 | Stack et al. | Jul 2001 | B1 |
6267776 | O'Connell | Jul 2001 | B1 |
6273913 | Wright et al. | Aug 2001 | B1 |
6280412 | Pederson et al. | Aug 2001 | B1 |
6281262 | Shikinami | Aug 2001 | B1 |
6284333 | Wang et al. | Sep 2001 | B1 |
6287332 | Bolz et al. | Sep 2001 | B1 |
6290721 | Heath | Sep 2001 | B1 |
6293966 | Frantzen | Sep 2001 | B1 |
6296655 | Gaudion et al. | Oct 2001 | B1 |
6303901 | Perry et al. | Oct 2001 | B1 |
6312459 | Huang et al. | Nov 2001 | B1 |
6327772 | Zadno-Azizi et al. | Dec 2001 | B1 |
6352547 | Brown et al. | Mar 2002 | B1 |
6375660 | Fischell et al. | Apr 2002 | B1 |
6375826 | Wang et al. | Apr 2002 | B1 |
6379381 | Hossainy et al. | Apr 2002 | B1 |
6387121 | Alt | May 2002 | B1 |
6388043 | Langer et al. | May 2002 | B1 |
6395326 | Castro et al. | May 2002 | B1 |
6409761 | Jang | Jun 2002 | B1 |
6423092 | Datta et al. | Jul 2002 | B2 |
6461632 | Gogolewski | Oct 2002 | B1 |
6464720 | Boatman et al. | Oct 2002 | B2 |
6479565 | Stanley | Nov 2002 | B1 |
6481262 | Ching et al. | Nov 2002 | B2 |
6485512 | Cheng | Nov 2002 | B1 |
6492615 | Flanagan | Dec 2002 | B1 |
6494908 | Huxel et al. | Dec 2002 | B1 |
6495156 | Wenz et al. | Dec 2002 | B2 |
6510722 | Ching et al. | Jan 2003 | B1 |
6511748 | Barrows | Jan 2003 | B1 |
6517559 | O'Connell | Feb 2003 | B1 |
6517888 | Weber | Feb 2003 | B1 |
6527801 | Dutta | Mar 2003 | B1 |
6537589 | Chae et al. | Mar 2003 | B1 |
6539607 | Fehring et al. | Apr 2003 | B1 |
6540777 | Stenzel | Apr 2003 | B2 |
6551303 | Van Tassel et al. | Apr 2003 | B1 |
6554854 | Flanagan | Apr 2003 | B1 |
6565599 | Hong et al. | May 2003 | B1 |
6569191 | Hogan | May 2003 | B1 |
6569193 | Cox et al. | May 2003 | B1 |
6572672 | Yadav et al. | Jun 2003 | B2 |
6574851 | Mirizzi | Jun 2003 | B1 |
6579305 | Lashinski | Jun 2003 | B1 |
6585755 | Jackson et al. | Jul 2003 | B2 |
6592614 | Lenker et al. | Jul 2003 | B2 |
6592617 | Thompson | Jul 2003 | B2 |
6613072 | Lau et al. | Sep 2003 | B2 |
6626939 | Burnside et al. | Sep 2003 | B1 |
6635269 | Jennissen | Oct 2003 | B1 |
6645243 | Vallana et al. | Nov 2003 | B2 |
6656162 | Santini, Jr. et al. | Dec 2003 | B2 |
6664335 | Krishnan | Dec 2003 | B2 |
6666214 | Canham | Dec 2003 | B2 |
6667049 | Janas et al. | Dec 2003 | B2 |
6669723 | Killion et al. | Dec 2003 | B2 |
6676697 | Richter | Jan 2004 | B1 |
6679980 | Andreacchi | Jan 2004 | B1 |
6689375 | Wahlig et al. | Feb 2004 | B1 |
6695920 | Pacetti et al. | Feb 2004 | B1 |
6706273 | Roessier | Mar 2004 | B1 |
6709379 | Brandau et al. | Mar 2004 | B1 |
6719934 | Stinson | Apr 2004 | B2 |
6719989 | Matsushima et al. | Apr 2004 | B1 |
6720402 | Langer et al. | Apr 2004 | B2 |
6745445 | Spilka | Jun 2004 | B2 |
6746773 | Llanos et al. | Jun 2004 | B2 |
6752826 | Holloway et al. | Jun 2004 | B2 |
6753007 | Haggard et al. | Jun 2004 | B2 |
6764504 | Wang et al. | Jul 2004 | B2 |
6764505 | Hossainy et al. | Jul 2004 | B1 |
6769161 | Brown et al. | Aug 2004 | B2 |
6818063 | Kerrigan | Nov 2004 | B1 |
6846323 | Yip et al. | Jan 2005 | B2 |
6863683 | Schwager et al. | Mar 2005 | B2 |
7008446 | Amis et al. | Mar 2006 | B1 |
7347869 | Hojeibane et al. | Mar 2008 | B2 |
7470281 | Tedeschi | Dec 2008 | B2 |
7563400 | Wilson et al. | Jul 2009 | B2 |
7722663 | Austin | May 2010 | B1 |
7731740 | LaFont et al. | Jun 2010 | B2 |
7763198 | Knott et al. | Jul 2010 | B2 |
7776926 | Hossainy et al. | Aug 2010 | B1 |
7947207 | Mcniven et al. | May 2011 | B2 |
8236039 | Mackiewicz et al. | Aug 2012 | B2 |
8309023 | Ramzipoor | Nov 2012 | B2 |
8333000 | Huang et al. | Dec 2012 | B2 |
8512388 | Roorda | Aug 2013 | B1 |
20010001128 | Holman et al. | May 2001 | A1 |
20010044652 | Moore | Nov 2001 | A1 |
20020002399 | Huxel et al. | Jan 2002 | A1 |
20020004060 | Heublein et al. | Jan 2002 | A1 |
20020004101 | Ding et al. | Jan 2002 | A1 |
20020007207 | Shin et al. | Jan 2002 | A1 |
20020035774 | Austin | Mar 2002 | A1 |
20020062148 | Hart | May 2002 | A1 |
20020065553 | Weber | May 2002 | A1 |
20020068967 | Drasler et al. | Jun 2002 | A1 |
20020111590 | Davila et al. | Aug 2002 | A1 |
20020116050 | Kocur | Aug 2002 | A1 |
20020138127 | Stiger et al. | Sep 2002 | A1 |
20020138133 | Lenz et al. | Sep 2002 | A1 |
20020161114 | Gunatillake et al. | Oct 2002 | A1 |
20030033001 | Igaki | Feb 2003 | A1 |
20030040772 | Hyodoh et al. | Feb 2003 | A1 |
20030055482 | Schwager et al. | Mar 2003 | A1 |
20030056360 | Brown et al. | Mar 2003 | A1 |
20030093107 | Parsonage et al. | May 2003 | A1 |
20030097172 | Shalev et al. | May 2003 | A1 |
20030100865 | Santini, Jr. et al. | May 2003 | A1 |
20030105518 | Dutta | Jun 2003 | A1 |
20030105530 | Pirhonen | Jun 2003 | A1 |
20030171053 | Sanders | Sep 2003 | A1 |
20030187495 | Cully et al. | Oct 2003 | A1 |
20030208227 | Thomas | Nov 2003 | A1 |
20030208259 | Penhasi | Nov 2003 | A1 |
20030209835 | Chun et al. | Nov 2003 | A1 |
20030212450 | Schlick | Nov 2003 | A1 |
20030226833 | Shapovalov et al. | Dec 2003 | A1 |
20030236563 | Fifer | Dec 2003 | A1 |
20040073155 | Laufer et al. | Apr 2004 | A1 |
20040093077 | White et al. | May 2004 | A1 |
20040098095 | Burnside et al. | May 2004 | A1 |
20040106973 | Johnson | Jun 2004 | A1 |
20040111149 | Stinson | Jun 2004 | A1 |
20040127880 | Weber | Jul 2004 | A1 |
20040133263 | Dusbabek et al. | Jul 2004 | A1 |
20040138731 | Johnson | Jul 2004 | A1 |
20040143317 | Stinson et al. | Jul 2004 | A1 |
20040167610 | Fleming, III | Aug 2004 | A1 |
20040199246 | Chu et al. | Oct 2004 | A1 |
20050096735 | Hojeibane et al. | May 2005 | A1 |
20050118344 | Pacetti | Jun 2005 | A1 |
20050143752 | Schwager et al. | Jun 2005 | A1 |
20050154450 | Larson et al. | Jul 2005 | A1 |
20050183259 | Eidenschink et al. | Aug 2005 | A1 |
20050203606 | VanCamp | Sep 2005 | A1 |
20050267408 | Grandt et al. | Dec 2005 | A1 |
20050283962 | Boudjemline | Dec 2005 | A1 |
20060004328 | Joergensen et al. | Jan 2006 | A1 |
20060020285 | Niermann | Jan 2006 | A1 |
20060030923 | Gunderson | Feb 2006 | A1 |
20060041271 | Bosma et al. | Feb 2006 | A1 |
20060047336 | Gale et al. | Mar 2006 | A1 |
20060058863 | LaFont et al. | Mar 2006 | A1 |
20060100694 | Globerman | May 2006 | A1 |
20060229712 | Wilson et al. | Oct 2006 | A1 |
20060287708 | Ricci et al. | Dec 2006 | A1 |
20060288561 | Roach et al. | Dec 2006 | A1 |
20070006441 | Mcniven et al. | Jan 2007 | A1 |
20070204455 | Boyd et al. | Sep 2007 | A1 |
20070208370 | Hauser et al. | Sep 2007 | A1 |
20070255388 | Rudakov et al. | Nov 2007 | A1 |
20070289117 | Huang et al. | Dec 2007 | A1 |
20080097570 | Thornton et al. | Apr 2008 | A1 |
20080208118 | Goldman | Aug 2008 | A1 |
20090076448 | Consigny et al. | Mar 2009 | A1 |
20090105747 | Chanduszko et al. | Apr 2009 | A1 |
20090187210 | Mackiewicz | Jul 2009 | A1 |
20090187211 | Mackiewicz | Jul 2009 | A1 |
20090292347 | Asmus et al. | Nov 2009 | A1 |
20100152765 | Haley | Jun 2010 | A1 |
20110106234 | Grandt | May 2011 | A1 |
20110257675 | Mackiewicz | Oct 2011 | A1 |
20120035704 | Grandt | Feb 2012 | A1 |
20120259402 | Grandt | Oct 2012 | A1 |
20120283814 | Huang et al. | Nov 2012 | A1 |
20130239396 | Schwager et al. | Sep 2013 | A1 |
20130269168 | Huang et al. | Oct 2013 | A1 |
Number | Date | Country |
---|---|---|
44 07 079 | Sep 1994 | DE |
195 09 464 | Jun 1996 | DE |
197 31 021 | Jan 1999 | DE |
198 56 983 | Dec 1999 | DE |
0 108 171 | May 1984 | EP |
0 144 534 | Jun 1985 | EP |
0 364 787 | Apr 1990 | EP |
0 397 500 | Nov 1990 | EP |
0 464 755 | Jan 1992 | EP |
0 493 788 | Jul 1992 | EP |
0 554 082 | Aug 1993 | EP |
0 578 998 | Jan 1994 | EP |
0 604 022 | Jun 1994 | EP |
0 621 017 | Oct 1994 | EP |
0 623 354 | Nov 1994 | EP |
0 665 023 | Aug 1995 | EP |
0 709 068 | May 1996 | EP |
0 716 836 | Jun 1996 | EP |
0 787 020 | Aug 1997 | EP |
0 935 952 | Aug 1999 | EP |
0 970 711 | Jan 2000 | EP |
1 000 591 | May 2000 | EP |
1 226 798 | Jul 2002 | EP |
1 295 570 | Mar 2003 | EP |
1 637 177 | Mar 2006 | EP |
2 029 052 | Mar 2009 | EP |
2 196 174 | Jun 2010 | EP |
2 322 118 | May 2011 | EP |
2 247 696 | Mar 1992 | GB |
WO 1989003232 | Apr 1989 | WO |
WO 1990001969 | Mar 1990 | WO |
WO 1990004982 | May 1990 | WO |
WO 1990006094 | Jun 1990 | WO |
WO 199117744 | Nov 1991 | WO |
WO 199117789 | Nov 1991 | WO |
WO 1992010218 | Jun 1992 | WO |
WO 1993006792 | Apr 1993 | WO |
WO 1994021196 | Sep 1994 | WO |
WO 1995029647 | Nov 1995 | WO |
WO 1998004415 | Feb 1998 | WO |
WO 1999003515 | Jan 1999 | WO |
WO 1999016382 | Apr 1999 | WO |
WO 1999016386 | Apr 1999 | WO |
WO 1999042147 | Aug 1999 | WO |
WO 1999055255 | Nov 1999 | WO |
WO 2000012147 | Mar 2000 | WO |
WO 2000064506 | Nov 2000 | WO |
WO 2000078249 | Dec 2000 | WO |
WO 2001001890 | Jan 2001 | WO |
WO 2001005462 | Jan 2001 | WO |
WO 2001021110 | Mar 2001 | WO |
WO 2002102283 | Dec 2002 | WO |
WO 2004023985 | Mar 2004 | WO |
WO 2004047681 | Jun 2004 | WO |
WO 2005053937 | Jun 2005 | WO |
WO 2006110861 | Oct 2006 | WO |
WO 2007061927 | May 2007 | WO |
WO 2008024491 | Feb 2008 | WO |
WO 2008024621 | Feb 2008 | WO |
WO 2008033621 | Mar 2008 | WO |
WO 2009066330 | May 2009 | WO |
WO 2009086205 | Jul 2009 | WO |
WO 2010066446 | Jun 2010 | WO |
WO 2011050979 | May 2011 | WO |
Entry |
---|
U.S. Appl. No. 61/016,266, filed Dec. 21, 2007, Mackiewicz. |
U.S. Appl. No. 61/138,455, filed Dec. 17, 2008, Haley. |
U.S. Appl. No. 13/502,084, filed Oct. 29, 2010, Grandt. |
U.S. Appl. No. 09/957,216, filed Sep. 19, 2001, U.S. Pat. No. 6,863,683, Mar. 8, 2005. |
U.S. Appl. No. 11/064,692, filed Feb. 23, 2005, U.S. Pat. No. 9,295,570, Mar. 29, 2016. |
U.S. Appl. No. 11/471,375, filed Jun. 29, 2006, U.S. Pat. No. 8,333,000, Dec. 18, 2012. |
U.S. Appl. No. 13/551,538, filed Jul. 17, 2012, U.S. Pat. No. 8,925,177, Jan. 6, 2015. |
U.S. Appl. No. 13/779,636, filed Feb. 27, 2013, U.S. Pat. No. 9,259,341, Feb. 16, 2016. |
U.S. Appl. No. 13/779,683, filed Feb. 27, 2013, U.S. 2013/0239396, Sep. 19, 2013. |
U.S. Appl. No. 14/552,066, filed Nov. 24, 2014, U.S. Pat. No. 9,579,225, Feb. 28, 2017. |
U.S. Appl. No. 09/957,216, Jan. 31, 2005 Issue Fee payment. |
U.S. Appl. No. 09/957,216, Feb. 16, 2005 Issue Notification. |
U.S. Appl. No. 09/957,216, Nov. 4, 2004 Notice of Allowance. |
U.S. Appl. No. 09/957,216, Sep. 17, 2004 Response to Non-Final Office Action. |
U.S. Appl. No. 09/957,216, Jun. 14, 2004 Non-Final Office Action. |
U.S. Appl. No. 09/957,216, Mar. 8, 2004 Response to Non-Final Office Action. |
U.S. Appl. No. 09/957,216, Sep. 26, 2003 Non-Final Office Action. |
U.S. Appl. No. 09/957,216, Aug. 4, 2003 Response to Restriction Requirement. |
U.S. Appl. No. 09/957,216, Jun. 10, 2003 Restriction Requirement. |
U.S. Appl. No. 11/064,692, Jul. 25, 2014 Response to Non-Final Office Action. |
U.S. Appl. No. 11/064,692, Jan. 15, 2014 Response to Non-Final Office Action. |
U.S. Appl. No. 11/064,692, Feb. 19, 2016 Issue Fee Payment. |
U.S. Appl. No. 11/064,692, Nov. 19, 2015 Notice of Allowance. |
U.S. Appl. No. 11/064,692, Aug. 3, 2015 Response to Non-Final Office Action. |
U.S. Appl. No. 11/064,692, Apr. 1, 2015 Non-Final Office Action. |
U.S. Appl. No. 11/064,692, Nov. 24, 2014 Amendment and Request for Continued Examination (RCE). |
U.S. Appl. No. 11/064,692, Aug. 26, 2014 Final Office Action. |
U.S. Appl. No. 11/064,692, Jan. 7, 2014 Amendment and Request for Continued Examination (RCE). |
U.S. Appl. No. 11/064,692, Feb. 25, 2014 Non-Final Office Action. |
U.S. Appl. No. 11/064,692, Oct. 2, 2013 Final Office Action. |
U.S. Appl. No. 11/064,692, Sep. 10, 2013 Response to Non-Final Office Action. |
U.S. Appl. No. 11/064,692, May 10, 2013 Non-Final Office Action. |
U.S. Appl. No. 11/064,692, Nov. 2, 2011 Amendment and Request for Continued Examination (RCE). |
U.S. Appl. No. 11/064,692, Aug. 2, 2011 Final Office Action. |
U.S. Appl. No. 11/064,692, Jun. 29, 2011 Response to Non-Final Office Action. |
U.S. Appl. No. 11/064,692, Mar. 29, 2011 Non-Final Office Action. |
U.S. Appl. No. 11/064,692, Feb. 23, 2010 Amendment and Request for Continued Examination (RCE). |
U.S. Appl. No. 11/064,692, Nov. 23, 2009 Final Office Action. |
U.S. Appl. No. 11/064,692, Jul. 31, 2009 Response to Non-Final Office Action. |
U.S. Appl. No. 11/064,692, Mar. 31, 2009 Non-Final Office Action. |
U.S. Appl. No. 11/064,692, Feb. 17, 2009 Amendment and Request for Continued Examination (RCE). |
U.S. Appl. No. 11/064,692, Oct. 14, 2008 Final Office Action. |
U.S. Appl. No. 11/064,692, Jul. 21, 2008 Response to Non-Final Office Action. |
U.S. Appl. No. 11/064,692, Feb. 21, 2008 Non-Final Office Action. |
U.S. Appl. No. 11/471,375, Nov. 14, 2012 Issue Fee payment. |
U.S. Appl. No. 11/471,375, Aug. 17, 2012 Notice of Allowance. |
U.S. Appl. No. 11/471,375, Jun. 12, 2012 Response to Final Office Action. |
U.S. Appl. No. 11/471,375, Apr. 13, 2012 Final Office Action. |
U.S. Appl. No. 11/471,375, Mar. 8, 2012 Response to Non-Final Office Action. |
U.S. Appl. No. 11/471,375, Dec. 8, 2011 Non-Final Office Action. |
U.S. Appl. No. 11/471,375, Jun. 16, 2011 Response to Non-Final Office Action. |
U.S. Appl. No. 11/471,375, Mar. 16, 2011 Non-Final Office Action. |
U.S. Appl. No. 11/471,375, Jan. 18, 2011 Amendment and Request for Continued Examination (RCE). |
U.S. Appl. No. 11/471,375, Sep. 15, 2010 Final Office Action. |
U.S. Appl. No. 11/471,375, Aug. 20, 2010 Response to Non-Final Office Action. |
U.S. Appl. No. 11/471,375, Aug. 5, 2010 Non-Final Office Action. |
U.S. Appl. No. 11/471,375, Mar. 29, 2010 Response to Non-Final Office Action. |
U.S. Appl. No. 11/471,375, Feb. 2, 2010 Non-Final Office Action. |
U.S. Appl. No. 11/471,375, Oct. 6, 2009 Response to Non-Final Office Action. |
U.S. Appl. No. 11/471,375, Jul. 6, 2009 Non-Final Office Action. |
U.S. Appl. No. 13/551,538, Nov. 13, 2013 Final Office Action. |
U.S. Appl. No. 13/551,538, Sep. 10, 2013 Response to Non-Final Office Action. |
U.S. Appl. No. 13/551,538, Jun. 10, 2013 Non-Final Office Action. |
U.S. Appl. No. 13/551,538, Apr. 15, 2014 Non-Final Office Action. |
U.S. Appl. No. 13/551,538, Jun. 19, 2014 Applicant Initiated Interview Summary. |
U.S. Appl. No. 13/551,538, Jul. 15, 2014 Response to Non-Final Office Action. |
U.S. Appl. No. 13/551,538, Sep. 19, 2014 Notice of Allowance. |
U.S. Appl. No. 13/551,538, Nov. 24, 2014 Issue Fee Payment. |
U.S. Appl. No. 13/779,636, Dec. 18, 2013 Non-Final Office Action. |
U.S. Appl. No. 13/779,636, Aug. 22, 2014 Final Office Action. |
U.S. Appl. No. 13/779,636, Nov. 24, 2014 Amendment and Request for Continued Examination (RCE). |
U.S. Appl. No. 13/779,636, Dec. 29, 2014 Non-Final Office Action. |
U.S. Appl. No. 13/779,636, Mar. 30, 2015 Response to Non-Final Office Action. |
U.S. Appl. No. 13/779,636, Jun. 5, 2015 Final Office Action. |
U.S. Appl. No. 13/779,636, Sep. 4, 2015 Amendment and Request for Continued Examination (RCE). |
U.S. Appl. No. 13/779,636, Jan. 5, 2016 Issue Fee Payment. |
U.S. Appl. No. 13/779,636, Oct. 5, 2015 Notice of Allowance. |
U.S. Appl. No. 13/779,636, Sep. 10, 2015 Applicant Initiated Interview Summary. |
U.S. Appl. No. 13/779,683, Mar. 7, 2017 Notice of Appeal Filed. |
U.S. Appl. No. 13/779,683, Oct. 7, 2016 Final Office Action. |
U.S. Appl. No. 13/779,683, Sep. 7, 2016 Amendment and Request for Continued Examination (RCE). |
U.S. Appl. No. 13/779,683, Apr. 7, 2016 Final Office Action. |
U.S. Appl. No. 13/779,683, Jan. 29, 2016 Applicant Initiated Interview Summary. |
U.S. Appl. No. 13/779,683, Jan. 26, 2016 Response to Non-Final Office Action. |
U.S. Appl. No. 13/779,683, Sep. 25, 2015 Non-Final Office Action. |
U.S. Appl. No. 13/779,683, Jun. 27, 2014 Applicant Initiated Interview Summary. |
U.S. Appl. No. 14/552,066, Jan. 11, 2017 Issue Fee Payment. |
U.S. Appl. No. 14/552,066, Oct. 11, 2016 Notice of Allowance |
U.S. Appl. No. 14/552,066, Aug. 29, 2016 Amendment and Request for Continued Examination (RCE). |
U.S. Appl. No. 14/552,066, Jun. 27, 2016 Response after Final Office Action. |
U.S. Appl. No. 15/552,066, Apr. 27, 2016 Final Office Action. |
U.S. Appl. No. 15/552,066, Feb. 1, 2016 Applicant Initiated Interview Summary. |
U.S. Appl. No. 15/552,066, Jan. 29, 2016 Response to Non-Final Office Action. |
U.S. Appl. No. 15/552,066, Jul. 29, 2015 Non-Final Office Action. |
Anonymous, “Bioabsorbable stent mounted on a catheter having optical coherence tomography capabilities”, Research Disclosure, pp. 1159-1162, (2004). |
Ansari, “End-to-end tubal anastomosis using an absorbable stent”, Fertility and Sterility, 32(2):197-201 (1979). |
Ansari, “Tubal Reanastomosis Using Absorbable Stent”, International Journal of Fertility, 23(4):242-243 (1978). |
Bull, “Parylene Coating for Medical Applications”, Medical Product Manufacturing News, 18:1 (1993). |
Casper, et al., “Fiber-Reinforced Absorbable Composite for Orthopedic Surgery”, Polymeric Materials Science and Engineering, 53:497-501 (1985). |
Detweiler, et al., “Gastrointestinal Sutureless Anastomosis Using Fibrin Glue: Reinforcement of the Sliding Absorbable Intraluminal Nontoxic Stent and Development of a Stent Placement Device”, Journal of Investigative Surgery, 9(2):111-130 (1996). |
Detweiler, et al., “Sliding, Absorbable, Reinforced Ring and an Axially Driven Stent Placement Device for Sutureless Fibrin Glue Gastrointestinal Anastomisis”, Journal of Investigative Surgery, 9(6):495-504 (1996). |
Detweiler, et al., “Sutureless Anastomosis of the Small Intestine and the Colon in Pigs Using an Absorbable Intraluminal Stent and Fibrin Glue”, Journal of Investigative Surgery, 8(2):129-140 (1995). |
Detweiler, et al., “Sutureless Cholecystojejunostomu in Pigs Using an Absorbable Intraluminal Stent and Fibrin Glue”, Journal of Investigative Surgery, 9(1):13-26 (1996). |
Devanathan, et al., “Polymeric Conformal Coatings for Implantable Electronic Devices”, IEEE Transactions on Biomedical Engineering, BME-27(11):671-675 (1980). |
Elbert, et al., “Conjugate Addition Reactions Combined with Free-Radical Cross-Linking for the Design of Materials for Tissue Engineering”, Biomacromolecules, 2(2):430-441 (2001). |
European Opposition dated Feb. 7, 2015 against European Patent EP 2066263. |
European Search Report for EP Application No. 07809699.7, dated Jun. 12, 2009. |
Hahn, et al., “Biocompatibility of Glow-Discharge-Polymerized Films and Vacuum-Deposited Parylene”, J Applied Polymer Sci, 38:55-64 (1984). |
Hahn, et al., “Glow Discharge Polymers as Coatings for Implanted Devices”, ISA, pp. 109-111 (1981). |
He, et al., “Assessment of Tissue Blood Flow Following Small Artery Welding with a Intraluminal Dissolvable Stent”, Microsurgery, 19(3):148-152 (1999). |
International Search Report for PCT/US2007/014331, dated Dec. 28, 2007. |
Kelley, et al., “Totally Resorbable High-Strength Composite Material”, Advances in Biomedical Polymers, 35:75-85 (1987). |
Kubies, et al., “Microdomain Structure in polylactide-block-poly(ethylene oxide) copolymer films”, Biomaterials, 21(5):529-536 (2000). |
Kutryk, et al., “Coronary Stenting: Current Perspectives”, a companion to the Handbook of Coronary Stents, pp. 1-16 (1999). |
Martin, et al., “Enhancing the biological activity of immobilized osteopontin using a type-1 collagen affinity coating”, J. Biomed. Mater Res, 70A:10-19 (2004). |
Mauduit, et al., “Hydrolytic degradation of films prepared from blends of high and low molecular weight poly(DL-lactic acid)s”, J. Biomed. Mater. Res., 30(2):201-207 (1996). |
Middleton, et al., “Synthetic biodegradable polymers as orthopedic devices”, Biomaterials, 21(23):2335-2346 (2000). |
Muller, et al., “Advances in Coronary Angioplasty: Endovascular Stents”, Coron. Arter. Dis., 1(4):438-448 (1990). |
Nichols, et al., “Electrical Insulation of Implantable Devices by Composite Polymer Coatings”, ISA Transactions, 26(4):15-18 (1987). |
Peuster, et al., “A novel approach to temporary stenting: degradable cardiovascular stents produced from corrodible metal-results 6-18 months after implantation into New Zealand white rabbits”, Heart, 86(5):563-569 (2001). |
Pietrzak, et al., “Bioabsorbable Fixation Devices: Status for the Craniomaxillofacial Surgeon”, J. Craniofaxial Surg., 8(2):92-96 (1997). |
Pietrzak, et al., “Bioresorbable implants—practical considerations”, Bone, 19(1):109S-119S (Supplement Jul. 1996). |
Redman, “Clinical Experience with Vasovasostomy Utilizing Absorbable Intravasal Stent”, Urology, 20(1):59-61 (1982). |
Rust, et al., “The Effect of Absorbable Stenting on Postoperative Stenosis of the Surgically Enlarged Maxillary Sinus Ostia in a Rabbit Animal Model”, Archives of Otolaryngology, 122(12):1395-1397 (1996). |
Schatz, “A View of Vascular Stants”, Circulation, 79(2):445-457 (1989). |
Schmidt, et al., “Long-Term Implants of Parylene-C Coated Microelectrodes”, Med & Biol Eng & Comp, 26(1):96-101 (1988). |
Spagnuolo, et al., “Gas 1 is induced by VE-cadherin and vascular endothelial growth factor and inhibits endothelial cell apoptosis”, Blood, 103(8):3005-3012 (2004). |
Tamai, et al., “Initial and 6-Month Results of Biodegradable Poly-I-Lactic Acid Coronary Stents in Humans”, Circulation, 102(4):399-404 (2000). |
Tsuji, et al., “Biodegradable Polymeric Stents”, Current Interventional Cardiology Reports, 3(1):10-17 (2001). |
Volkel, et al., “Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin(CD105)”, Biochimica et Biophysica Acta, 1663(1-2):158-166 (2004). |
Von Recum, et al., “Degradation of polydispersed poly(L-lactic acid) to modulate lactic acid release”, Biomaterials, 16(6):441-445 (1995). |
Yau, et al., “Modern Size-Exclusion Liquid Chromatography”, Wiley-Interscience Publication, Table of Contents IX-XV (1979). |
Number | Date | Country | |
---|---|---|---|
20170119564 A1 | May 2017 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14552066 | Nov 2014 | US |
Child | 15403324 | US | |
Parent | 13779636 | Feb 2013 | US |
Child | 14552066 | US | |
Parent | 13551538 | Jul 2012 | US |
Child | 13779636 | US | |
Parent | 11471375 | Jun 2006 | US |
Child | 13551538 | US |